Kimberly Dulaney, MD
Cardiovascular Disease · Colorado Springs, CONPI 1356421622
Payments from drug & device makers
Across 300 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$839
- Pfizer$679
- Amgen$638
- E.r. Squibb & Sons, L.L.C.$569
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$369
- Merck$311
- plus $3K from 32 others
What the payments were for
- Consulting fees$371%
- Food & beverage$6,00699%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 46 | $839 |
| Pfizer | 37 | $679 |
| Amgen | 33 | $638 |
| E.r. Squibb & Sons, L.L.C. | 39 | $569 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $369 |
| Merck | 16 | $311 |
| Boehringer Ingelheim | 16 | $303 |
| Impulse Dynamics (USA) Inc. | 4 | $249 |
| Heartflow, Inc. | 5 | $230 |
| Actelion Pharmaceuticals US, Inc. | 9 | $192 |
| Johnson & Johnson | 8 | $153 |
| Scpharmaceuticals Inc. | 6 | $127 |
| AstraZeneca | 8 | $127 |
| Cvrx, Inc. | 5 | $124 |
| Abbott | 1 | $113 |
| Philips North America LLC | 6 | $111 |
| Alnylam Pharmaceuticals Inc. | 4 | $107 |
| Baxter Healthcare | 3 | $93 |
| Kestra Medical Technology Services, Inc. | 4 | $93 |
| Novo Nordisk | 3 | $71 |
| Bridgebio Pharma, Inc. | 3 | $66 |
| Bayer | 3 | $62 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Cleerly, Inc. | 2 | $47 |
| Bardy Diagnostics, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| GE HealthCare | 1 | $26 |
| Edwards Lifesciences | 1 | $26 |
| Abiomed | 1 | $21 |
| Ossur Americas, Inc. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Biotronik Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$302
- MitraClip System$113
How this compares
$6,057 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $321,498 |
| EntrestoSacubitril/Valsartan | 232 | $309,864 |
| XareltoRivaroxaban | 72 | $93,410 |
| JardianceEmpagliflozin | 70 | $83,244 |
| FarxigaDapagliflozin Propanediol | 40 | $43,917 |
| Repatha SureclickEvolocumab | 26 | $28,123 |
| Metoprolol Succinate | 367 | $6,067 |
| Praluent PenAlirocumab | 12 | $5,924 |
| Potassium Chloride | 77 | $5,080 |
| Atorvastatin Calcium | 248 | $1,713 |
| Nebivolol Hcl | 20 | $1,518 |
| Amlodipine Besylate | 234 | $1,501 |
| Rosuvastatin Calcium | 110 | $1,373 |
| Carvedilol | 179 | $1,254 |
| Hydralazine Hcl | 92 | $1,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $679 | $321,498267 claims |
| NovartisEntresto | $839 | $309,864232 claims |
| Johnson & JohnsonXarelto | $153 | $93,41072 claims |
| Boehringer IngelheimJardiance | $303 | $83,24470 claims |
| AstraZenecaFarxiga | $127 | $43,91740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Colorado Springs
- Timothy HegemanColorado Springs$283K
- Deborah JalowiecColorado Springs$106K
- David GreenbergColorado Springs$20K
- Gary LuckasenFort Collins$11M
- Payal KohliAurora$1.7M
- Marc BonacaAurora$1.2M
- William SauerAurora$978K
- John AltmanLakewood$797K
- Nampalli VijayDenver$711K
- Brack HattlerAurora$699K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.